The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
Abstract
New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV-1 resistance testing. Published data and presentations at scientific conferences, as well as strength of the evidence, were considered. Properly used resistance testing can improve virological outcome among HIV-infected individuals. Resistance testing is recommended in cases of acute or recent HIV infection, for certain patients who have been infected as long as 2 years or more prior to initiating therapy, in cases of antiretroviral failure, and during pregnancy. Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R., et al. (1997) · Science · doi:10.1126/science.278.5341.1295 · Cited by 3,098
Self-citationRecovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186
Self-citationVigorous HIV-1-Specific CD4 + T Cell Responses Associated with Control of Viremia
Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. A., & Walker, B. D. (1997) · Science · doi:10.1126/science.278.5342.1447 · Cited by 1,835
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Larder, B. A., Darby, G., & Richman, D. D. (1989) · Science · doi:10.1126/science.2467383 · Cited by 1,559
Self-citationMultiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV
Little, S. J., Holte, S., Routy, J.-P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013552 · Cited by 1,140
Self-citationKilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., et al. (1995) · Nature · doi:10.1038/374569a0 · Cited by 974
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Self-citationSperling, R. S., Shapiro, D. E., Coombs, R. W., Todd, J. A., Herman, S. A., McSherry, G. D., O'Sullivan, M. J., Van Dyke, R. B., Jimenez, E., Rouzioux, C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352201 · Cited by 803
Hirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Self-citationDrug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
Durant, J., Clevenbergh, P. A., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J., & Dellamonica, P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12291-2 · Cited by 752
Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level
Moore, C. B., John, M., James, I. R., Christiansen, F. T., Witt, C. S., & Mallal, S. A. (2002) · Science · doi:10.1126/science.1069660 · Cited by 740
Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 709
Self-citationResistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Self-citationDeeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440702 · Cited by 653
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
Richman, D. D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S. A., Sullivan, J., Cheeseman, S., Barringer, K., & Pauletti, D. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.1660-1666.1994 · Cited by 576
Self-citationHirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vézinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., et al. (1998) · JAMA · doi:10.1001/jama.279.24.1984 · Cited by 563
Self-citation(2002) · PsycEXTRA Dataset · doi:10.1037/e548362006-001 · Cited by 517
Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A., Mannheimer, S., Thompson, M., Abrams, D. I., Brizz, B., et al. (2000) · AIDS · doi:10.1097/00002030-200006160-00001 · Cited by 494
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
Rimsky, L. T., Shugars, D. C., & Matthews, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.986-993.1998 · Cited by 423
Kellam, P., Boucher, C. A., & Larder, B. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1934 · Cited by 413
Back, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., van Kuilenburg, A. B., van Gennip, A. H., & Berkhout, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00777.x · Cited by 406
Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1
Martinez-Picado, J., Savara, A. V., Sutton, L., & D’Aquila, R. T. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3744-3752.1999 · Cited by 396
Self-citationShirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L., Chokekijchai, S., Roy, B. M., Arnold, E., & Yarchoan, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2398 · Cited by 386
Descamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 367
Boucher, C. A. B., O'Sullivan, E., Mulder, J. W., Ramautarsing, C., Kellam, P., Darby, G., Lange, J. M. A., Goudsmit, J., & Larder, B. A. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/165.1.105 · Cited by 352
Arion, D., Kaushik, N., McCormick, S., Borkow, G., & Parniak, M. A. (1998) · Biochemistry · doi:10.1021/bi981200e · Cited by 345
Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
Drug Resistance Mutations in HIV-1.
D’Aquila, R. T., Schapiro, J., Brun‐Vézinet, F., Clotet, B., Conway, B., Demeter, L. M., Grant, R. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., et al. (2002) · PubMed · Cited by 276
Self-citationIn vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA
Wainberg, M. A., Miller, M. D., Quan, Y., Salomon, H., Mulato, A. S., Lamy, P. D., Margot, N. A., Anton, K. E., & Cherrington, J. M. (1999) · Antiviral Therapy · doi:10.1177/135965359900400205 · Cited by 247
Iversen, A. K., Shafer, R. W., Wehrly, K., Winters, M. A., Mullins, J. I., Chesebro, B., & Merigan, T. C. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.1086-1090.1996 · Cited by 245
Use of Genotypic Resistance Testing To Guide HIV Therapy: Clinical Impact and Cost-Effectiveness
Weinstein, M. C., Goldie, S. J., Losina, E., Cohen, C. J., Baxter, J. D., Zhang, H., Kimmel, A. D., & Freedberg, K. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-6-200103200-00008 · Cited by 235
Quiñones-Mateu, M. E., Ball, S. C., Marozsan, A. J., Torre, V. S., Albright, J. L., Vanham, G., van der Groen, G., Colebunders, R. L., & Arts, E. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9222-9233.2000 · Cited by 234
Zolopa, A. R., Shafer, R. W., Warford, A. L., Montoya, J. G., Hsu, P., Katzenstein, D. A., Merigan, T. C., & Efron, B. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-11-199912070-00003 · Cited by 225
Durant, J., Clevenbergh, P., Garraffo, R., Halfon, P., Icard, S., Giudice, P. D., Montagne, N., Schapiro, J. M., & Dellamonica, P. (2000) · AIDS · doi:10.1097/00002030-200007070-00005 · Cited by 220
Winters, M. A., Coolley, K. L., Girard, Y. A., Levee, D. J., Hamdan, H., Shafer, R. W., Katzenstein, D. A., & Merigan, T. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4948 · Cited by 216
Cingolani, A., Antinori, A., Rizzo, M. G., Murri, R., Ammassari, A., Baldini, F., Di Giambenedetto, S., Cauda, R., & De Luca, A. (2002) · AIDS · doi:10.1097/00002030-200202150-00008 · Cited by 214
Jackson, J. B., Becker-Pergola, G., Guay, L. A., Musoke, P., Mracna, M., Fowler, M. G., Mofenson, L. M., Mirochnick, M., Mmiro, F., & Eshleman, S. H. (2000) · AIDS · doi:10.1097/00002030-200007280-00001 · Cited by 208
Impact of drug resistance mutations on virologic response to salvage therapy
Lorenzi, P., Opravil, M., Hirschel, B., Chave, J.-P., Furrer, H.-J., Sax, H., Vaclav Perneger, T., Perrin, L., Kaiser, L., & Yerly, S. (1999) · AIDS · doi:10.1097/00002030-199902040-00001 · Cited by 205
The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance
Hsiou, Y., Ding, J., Das, K., Clark, A. D., Boyer, P. L., Lewi, P., Janssen, P. A. J., Kleim, J.-P., Rösner, M., Hughes, S. H., et al. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4648 · Cited by 195
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., et al. (2002) · AIDS · doi:10.1097/00002030-200203080-00009 · Cited by 195
Therapeutic drug monitoring in HIV infection: current status and future directions
Back, D. J., Gatti, G., Fletcher, C. V., Garaffo, R., Haubrich, R., Hoetelmans, R. M. W., Kurowski, M., Luber, A., Merry, C., & Perno, C. F. (2002) · AIDS · doi:10.1097/00002030-200203001-00002 · Cited by 183
Götte, M., Arion, D., Parniak, M. A., & Wainberg, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3579-3585.2000 · Cited by 172
Deeks, S. G., Hellmann, N. S., Grant, R. M., Parkin, N. T., Petropoulos, C. J., Becker, M., Symonds, W., Chesney, M., & Volberding, P. A. (1999) · The Journal of Infectious Diseases · doi:10.1086/314775 · Cited by 164
Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance (2001) · BMJ · doi:10.1136/bmj.322.7294.1087 · Cited by 154
de Ronde, A., van Dooren, M., van der Hoek, L., Bouwhuis, D., de Rooij, E., van Gemen, B., de Boer, R. J., & Goudsmit, J. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.595-602.2001 · Cited by 121
Kemp, S. D., Shi, C., Bloor, S., Harrigan, P. R., Mellors, J. W., & Larder, B. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5093-5098.1998 · Cited by 119
Self-citationMusey, L. K., Krieger, J. N., Hughes, J. P., Schacker, T. W., Corey, L., & McElrath, M. J. (1999) · The Journal of Infectious Diseases · doi:10.1086/314868 · Cited by 115
Más, A., Parera, M., Briones, C., Soriano, V., Martı́nez, M. Á., Domingo, E., & Menéndez‐Arias, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5752 · Cited by 106
Duwe, S. C., Brunn, M., Altmann, D., Hamouda, O., Schmidt, B., Walter, H., Pauli, G., & cherer, C. K. ⁄. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200103010-00010 · Cited by 105
Nijhuis, M., Schuurman, R., de Jong, D. C. M., van Leeuwen, R., Lange, J. M. A., Danner, S. A., Keulen, W., de Groot, T. M., & Boucher, C. A. (1997) · The Journal of Infectious Diseases · doi:10.1086/514056 · Cited by 102
de Jong, J. J., Goudsmit, J., Lukashov, V. V., Hillebrand, M. E., Baan, E., Huismans, R., Danner, S. A., ten Veen, J. H., de Wolf, F., & Jurriaans, S. (1999) · AIDS · doi:10.1097/00002030-199901140-00010 · Cited by 100
Archer, R. H., Dykes, C., Gerondelis, P., Lloyd, A. L., Fay, P. J., Reichman, R. C., Bambara, R. A., & Demeter, L. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8390-8401.2000 · Cited by 99
Self-citationHypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1
Whitcomb, J. M., Huang, W., Limoli, K. L., Paxinos, E. E., Wrin, T., Skowron, G., Deeks, S. G., Bates, M. P., Hellmann, N. S., & Petropoulos, C. J. (2002) · AIDS · doi:10.1097/00002030-200210180-00002 · Cited by 96
Miller, V., & Larder, B. A. (2001) · Antiviral Therapy · doi:10.1177/135965350100603s03 · Cited by 93
Naeger, L. K., Margot, N., & Miller, M. D. (2001) · Antiviral Therapy · doi:10.1177/135965350100600205 · Cited by 92
Gerondelis, P., Archer, R. H., Palaniappan, C., Reichman, R. C., Fay, P. J., Bambara, R. A., & Demeter, L. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5803-5813.1999 · Cited by 86
Self-citationSchmit, J., Laethem, K. V., Ruiz, L., Hermans, P., Sprecher, S., Sönnerborg, A. B., Leal, M., Harrer, T., Clotet, B., Arendt, V., et al. (1998) · AIDS · doi:10.1097/00002030-199815000-00012 · Cited by 84
Self-citationShulman, N. S., Zolopa, A. R., Passaro, D., Shafer, R. W., Huang, W., Katzenstein, D. A., Israelski, D. M., Hellmann, N., Petropoulos, C., & Whitcomb, J. M. (2001) · AIDS · doi:10.1097/00002030-200106150-00007 · Cited by 78
Kavlick, M. F., Wyvill, K. M., Yarchoan, R., & Mitsuya, H. (1998) · The Journal of Infectious Diseases · doi:10.1086/515324 · Cited by 69
Kilby, J. M., Goepfert, P., Miller, A. P., Gnann, J. W., Sillers, M., Saag, M. S., & Bucy, R. P. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00011 · Cited by 62
Ren, J., Esnouf, R. M., Hopkins, A. L., Jones, E. Y., Kirby, I., Keeling, J., Ross, C., Larder, B. A., Stuart, D. I., & STAMMERS, D. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9518 · Cited by 61
Lennerstrand, J., Hertogs, K., STAMMERS, D. K., & Larder, B. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.7202-7205.2001 · Cited by 55
Daar, E. S., Bai, J., Hausner, M. A., Majchrowicz, M., Tamaddon, M., & Giorgi, J. V. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-10-199805150-00005 · Cited by 53
Gartland, M., Clumeck, N., Cooper, D., Gatell, J. M., Gazzard, B., Gerstoft, J., Goebel, F. D., Lange, J. M. A., Montaner, J. S. G., Reiss, P., et al. (2001) · Antiviral Therapy · doi:10.1177/135965350100600206 · Cited by 43
Self-citationKuritzkes, D. R., Shugarts, D. L., Bakhtiari, M., Poticha, D., Johnson, J., Rubin, M., Gingeras, T., Kennedy, M., & Eron, J. J. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200001010-00004 · Cited by 40
Self-citation
Cited by
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationTenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Aberg, J. A., Kaplan, J. E., Libman, H., Emmanuel, P., Anderson, J. R., Stone, V. E., Oleske, J. M., Currier, J. S., & Gallant, J. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605292 · Cited by 837
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
Metadata
- Authors
- Hirsch, M. S., Brun‐Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D’Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., Mellors, J. W., Jacobsen, D. M., & Richman, D. D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-07
- Volume
- 37
- Issue
- 1
- Pages
- 113-128
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2021877795
- Cited by
- 514
- References
- 70
- FWCI
- 52.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.